Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1B | P35368 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | MMP8 | P22894 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | MMP3 | P08254 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 3/20 | 0.36 |
| ▸ | MMP9 | P14780 | 3/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.35 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HRH1 | P35367 | 1/20 | 0.34 |
| ▸ | SCN1A | P35498 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11428427 | 0.89 | ADRA1B (0.42) | ADRA1BLMNACYP2C19TSHRMMP8 | |
| SCHEMBL8723000 | 0.80 | ADRA1B (0.46) | ADRA1BLMNATSHRMMP8MMP3 | |
| SCHEMBL15461426 | 0.79 | ADRA1B (0.47) | ADRA1BLMNACYP2C19TSHRMMP8 | |
| SCHEMBL14400476 | 0.77 | CYP2C19 (0.48) | ADRA1BLMNACYP2C19MMP2MMP9 | |
| SCHEMBL11432815 | 0.76 | FABP4 (0.44) | ADRA1BMMP8MMP3MMP2MMP9 | |
| SCHEMBL11304673 | 0.76 | ADRA1B (0.48) | ADRA1BLMNAMMP8MMP3PKM | |
| SCHEMBL11424253 | 0.75 | TDP1 (0.50) | CYP2C19CYP2D6MAPT | |
| SCHEMBL15461431 | 0.74 | OPRL1 (0.41) | ADRA1BLMNAALDH1A1PKM | |
| SCHEMBL14353736 | 0.72 | ALDH1A1 (0.42) | ADRA1BLMNACYP2C19TSHRMMP8 | |
| SCHEMBL15461429 | 0.72 | PKM (0.47) | ADRA1BLMNACYP2C19TSHRMMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2307344-B1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE | LIXTE BIOTECHNOLOGY INC (US) | 2015-07-29 | — | — | EP | disclosed |
| US-8541458-B2 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-20120264764-A1 | Oxabicycloheptanes and Oxabicycloheptenes, Their Preparation and Use | LIXTE BIOTECHNOLOGY, INC. | 2012-10-18 | — | — | US | disclosed |
| US-8227473-B2 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. (US) | 2012-07-24 | — | — | US | disclosed |
| EP-2307344-A1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE | Lixte Biotechnology, Inc. (US) | 2011-04-13 | — | — | EP | disclosed |
| WO-2010014254-A1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE | LIXTE BIOTECHNOLOGY, INC. (US) | 2010-02-04 | — | — | WO | disclosed |
| US-20100029484-A1 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. | 2010-02-04 | — | — | US | disclosed |
| US-5304645-A | Colored or fluorescent labels | BOEHRINGER MANNHEIM GMBH (DE) | 1994-04-19 | — | — | US | disclosed |
| US-4954630-A | COLORIMETRIC OR FLUORESCENT ANALYSIS | BOEHRINGER MANNHEIM GMBH (DE) | 1990-09-04 | — | — | US | disclosed |
| EP-0209875-B1 | RESORUFIN DERIVATIVES AND PROCESS FOR THEIR PREPARATION | Roche Diagnostics GmbH (DE) | 1990-08-29 | — | — | EP | disclosed |
| EP-0209875-A1 | Resorufin derivatives and process for their preparation | Roche Diagnostics GmbH (DE) | 1987-01-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029484-A1 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use | HCCS, OXA1L, OTC | ADRA1B 1798/4885LMNA 2628/4885CYP2C19 159/4885 |
| US-20120264764-A1 | Oxabicycloheptanes and Oxabicycloheptenes, Their Preparation and Use | HCCS, OXA1L, OTC | ADRA1B 1798/4885LMNA 2628/4885CYP2C19 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.